Recovery of sense of smell (as · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection
It is very uncertain whether palmitoylethanolamide and luteolin changes recovery of sense of smell (as compared with no intervention (very low certainty).
1 finding from 1 review
Disease‐related quality of life · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Presence of normal olfactory function · people with olfactory dysfunction for less than 4 weeks following COVID‐19 infection
It is very uncertain whether intranasal steroid spray changes presence of normal olfactory function Assessed by participants as a… compared with no intervention/placebo (very low certainty).
2 findings from 1 review
Other adverse effects · people with olfactory dysfunction for less than 4 weeks following COVID‐19 infection
1 finding from 1 review
Presence of normal olfactory function · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days
Intranasal steroid drops showed no clear difference in presence of normal olfactory function Assessed by participants > 4… compared with placebo (low certainty).
1 finding from 1 review
Serious adverse effects · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in sense of smell · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Prevalence of parosmia · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in taste · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Disease‐related quality of life · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Other adverse effects · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with olfactory dysfunction for less than 4 weeks following COVID‐19 infection
1 finding from 1 review
Change in sense of smell · people with olfactory dysfunction for less than 4 weeks following COVID‐19 infection
3 findings from 1 review
no estimate extracted
1 study · 77 participants
Very low
no estimate extracted
1 study · 100 participants
Very low
no estimate extracted
1 study · 77 participants
Low
Prevalence of parosmia · people with olfactory dysfunction for less than 4 weeks following COVID‐19 infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in taste · people with olfactory dysfunction for less than 4 weeks following COVID‐19 infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Disease‐related quality of life · people with olfactory dysfunction for less than 4 weeks following COVID‐19 infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Wait‐list compared with no‐treatment · patients with mental health disorders
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Non‐serious adverse events for all placebos compared with wait‐list or no treatment (Spontaneous reporting of dichotomous outcomes) (Post‐treatment) · patients with mental health disorders
It is very uncertain whether the intervention changes non‐serious adverse events for all placebos compared with wait‐list… (very low certainty).
1 finding from 1 review
Intervention not reported
Usual care compared with wait‐list/no‐treatment (Variety of continuous outcome) (Post‐treatment) · patients with mental health disorders
1 finding from 1 review
Intervention not reported
Serious adverse events for all placebos · patients with mental health disorders
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found